MK-0812

DB11990InvestigationalSmall molecule

MK0812 has been used in trials studying the treatment of Relapsing-Remitting Multiple Sclerosis.

Mechanism: Pharmacologically active on C-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₂₄H₃₆F₃N₃O₂ · 455.566 g/mol (avg)
Code names: MK-0812

Resolves to

Compound

Structure

InChIKeyUNVWTBOGMHPKJM-CWKRKGSWSA-NSMILESCO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](CN2CCC3=C(C2)C=C(C=N3)C(F)(F)F)(C1)C(C)C

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0812, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.